Home » EMA’s Approach to Process Validation Moves Closer to U.S. FDA’s Stance
EMA’s Approach to Process Validation Moves Closer to U.S. FDA’s Stance
September 10, 2012
While drugmakers should prepare for the most far-reaching approach to process validation, the U.S. Food and Drug Administration’s (FDA) lifecycle approach, they should also be aware of upcoming guidance from the European Medicines Agency (EMA), an expert says.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor